Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Sepantronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | SP1 | P08047 | 1/20 | 1.00 |
| ▸ | ILF3 | Q12906 | 1/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepantronium SCHEMBL29493286 | 1.00 | BIRC5 (1.00) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814447 | 0.99 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814857 | 0.99 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Bromide SCHEMBL15062823 | 0.89 | BIRC5 (0.79) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190071 | 0.86 | BIRC5 (0.74) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL16584072 | 0.84 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29379252 | 0.84 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190207 | 0.84 | BIRC5 (0.72) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29464041 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL6188375 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45105-E1 | Method of treating cancer by co-administration of anticancer agents | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | claimed |
| EP-1614686-B1 | BROMIDE AND ITS CRYSTAL | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | claimed |
| EP-2609920-A1 | Method of treating cancer by a combined therapy of YM-155 with other anticancer agents | Astellas Pharma Inc. (JP) | 2013-07-03 | — | — | EP | claimed |
| EP-2127652-B1 | METHOD FOR TREATING CANCER USING ANTICANCER AGENT IN COMBINATION | ASTELLAS PHARMA INC (JP) | 2013-05-15 | — | — | EP | claimed |
| US-8003105-B2 | Method of treating cancer by co-administration of anticancer agents | ASTELLAS PHARMA INC. (JP) | 2011-08-23 | — | — | US | claimed |
| EP-2127652-A1 | METHOD FOR TREATING CANCER USING ANTICANCER AGENT IN COMBINATION | Astellas Pharma Inc. (JP) | 2009-12-02 | — | — | EP | claimed |
| US-7618992-B2 | Method of treating cancer by co-administration of anticancer agents | ASTELLAS PHARMA INC. (JP) | 2009-11-17 | — | — | US | claimed |
| US-20090263390-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | claimed |
| US-20080166344-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-07-10 | — | — | US | claimed |
| US-20060223831-A1 | Bromide and its crystal | ASTELLAS PHARMA INC. (JP) | 2006-10-05 | — | — | US | claimed |
| EP-1614686-A1 | BROMIDE AND ITS CRYSTAL | Astellas Pharma Inc. (JP) | 2006-01-11 | — | — | EP | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| CN-1791595-A | Bromide and its crystal | YAMANOUCHI PHARMA CO LTD (JP) | 2006-06-21 | — | — | CN | disclosed |
| EP-1614686-A1 | BROMIDE AND ITS CRYSTAL | Astellas Pharma Inc. (JP) | 2006-01-11 | — | — | EP | disclosed |
| EP-1614686-A1 | BROMIDE AND ITS CRYSTAL | Astellas Pharma Inc. (JP) | 2006-01-11 | — | — | EP | disclosed |
| JP-2004331657-A | BROMIDE AND ITS CRYSTAL | YAMANOUCHI PHARMACEUT CO LTD | 2004-11-25 | — | — | JP | disclosed |
| WO-2004092160-A1 | BROMIDE AND ITS CRYSTAL | ASTELLAS PHARMA INC. (JP) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263390-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | DCK, TOP2A, RRM1 | BIRC5 441/4885RIPK2 590/4885SP1 4137/4885 |
| US-20060223831-A1 | Bromide and its crystal | B2M, PBRM1, POLM | BIRC5 1109/4885RIPK2 3146/4885SP1 4106/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | BIRC5 237/4885RIPK2 428/4885SP1 1611/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | BIRC5 237/4885RIPK2 428/4885SP1 1611/4885 |
| US-20080166344-A1 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS | DCK, TOP2A, RRM1 | BIRC5 441/4885RIPK2 590/4885SP1 4137/4885 |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | BIRC5 450/4885RIPK2 243/4885SP1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.